IGF2BP3 and lung adenocarcinoma: Subsequent analysis demonstrated that IGF2BP3 levels were markedly elevated in individuals diagnosed with mid-to-late stage lung adenocarcinoma, starkly contrasting with those in the early stages of the condition.